載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.4061
+US$0.0479 · +13.37%
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
前收盤價
US$0.4061
+US$0.0479 · +13.37%
盤中時間採用ET。市場資料可能有所延遲。
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
日內區間
目前US$0.4061
52週區間
目前US$0.4061
盤中時間採用ET。市場資料可能有所延遲。
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
日內區間
目前US$0.4061
52週區間
目前US$0.4061
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.55億 USD | 1.44億 USD | 1.27億 USD | 1.08億 USD | 8634.6萬 USD |
| 銷貨成本 | 4134.7萬 USD | 3864.8萬 USD | 6510.5萬 USD | 5487.4萬 USD | 4602.1萬 USD |
| 毛利 | 1.14億 USD | 1.06億 USD | 6193.9萬 USD | 5279.8萬 USD | 4032.5萬 USD |
| 研究與開發 | 1242.9萬 USD | 1668.3萬 USD | 3913.3萬 USD | 8270.4萬 USD | 1.31億 USD |
| 銷售、一般及管理費用 | 1.04億 USD | 1億 USD | 1.2億 USD | 1.45億 USD | 1.27億 USD |
| 營業費用 | 1.16億 USD | 1.17億 USD | 1.73億 USD | 2.27億 USD | 2.58億 USD |
| 利息收入 | — | 355萬 USD | 336.4萬 USD | 163.8萬 USD | 43.3萬 USD |
| 利息支出 | — | 603.2萬 USD | 386.8萬 USD | 247.4萬 USD | 241萬 USD |
| 折舊和攤銷 | 231.4萬 USD | 249.2萬 USD | 289.9萬 USD | 288.9萬 USD | 302.1萬 USD |
| 營業利益 | −253.8萬 USD | −1152.8萬 USD | −1.11億 USD | −1.75億 USD | −2.18億 USD |
| 淨利 | −2019.5萬 USD | −1358萬 USD | −1.11億 USD | −1.82億 USD | −2.21億 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.67
上漲空間 1542.45%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI174.1萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM134.87萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF66.8萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO32.76萬0.00%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO29.1萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC16.72萬0.01%13.17億 USD0.60%US$183+0.11%
Invesco NASDAQ Future Gen 200 ETFQQQS15.31萬0.67%2275.83萬 USD0.20%US$42.145+1.39%
Vanguard Health Care ETFVHT10.41萬0.00%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
